242 related articles for article (PubMed ID: 33459088)
1. Budget impact analysis of Jivi (damoctocog alfa pegol, Bay 94-9027) in severe hemophilia A in Japan.
Fujii T; Kidoguchi Y; Takahashi N; Yu E; Ainiwaer D; Byrne A
J Med Econ; 2021; 24(1):218-225. PubMed ID: 33459088
[TBL] [Abstract][Full Text] [Related]
2. Damoctocog Alfa Pegol: A Review in Haemophilia A.
Paik J; Deeks ED
Drugs; 2019 Jul; 79(10):1147-1156. PubMed ID: 31218660
[TBL] [Abstract][Full Text] [Related]
3. A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients.
Yan S; Maro GS; Desai V; Simpson ML
J Manag Care Spec Pharm; 2020 Oct; 26(10):1258-1265. PubMed ID: 32820685
[TBL] [Abstract][Full Text] [Related]
4. Budget impact of prophylactic treatment of rVIII-SingleChain in moderate and severe hemophilia A in Italy.
Di Brino E; Yan S; Tomic R; Panebianco M; Dlotko E; Stern L; Basile M; Rumi F; Cicchetti A; Marino R
J Med Econ; 2023; 26(1):554-564. PubMed ID: 37039544
[TBL] [Abstract][Full Text] [Related]
5. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis.
Mancuso ME; Reding MT; Negrier C; Kerlin BA; Rangarajan S; Simpson ML
Thromb Haemost; 2021 Aug; 121(8):1079-1086. PubMed ID: 33296943
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective.
Benson G; Morton T; Thomas H; Lee XY
Clinicoecon Outcomes Res; 2021; 13():39-51. PubMed ID: 33500640
[TBL] [Abstract][Full Text] [Related]
7. A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States.
Aledort L; Milligan S; Watt M; Booth J
J Manag Care Spec Pharm; 2020 Apr; 26(4):492-503. PubMed ID: 32223610
[TBL] [Abstract][Full Text] [Related]
8. Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada.
Matino D; Germini F; Chan AKC; Decker K; Iserman E; Chelle P; Edginton AN; Oladoyinbo O; Trinari E; Keepanasseril A; Iorio A
Haemophilia; 2024 Mar; 30(2):345-354. PubMed ID: 38379181
[TBL] [Abstract][Full Text] [Related]
9. Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.
Solms A; Shah A; Berntorp E; Tiede A; Iorio A; Linardi C; Ahsman M; Mancuso ME; Zhivkov T; Lissitchkov T
Ann Hematol; 2020 Nov; 99(11):2689-2698. PubMed ID: 32974838
[TBL] [Abstract][Full Text] [Related]
10. Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective.
Lorenzoni V; Triulzi I; Turchetti G
BMC Health Serv Res; 2018 Aug; 18(1):596. PubMed ID: 30071878
[TBL] [Abstract][Full Text] [Related]
11. Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey.
Zanon E
Pharmaceuticals (Basel); 2023 Aug; 16(9):. PubMed ID: 37765002
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
Henry N; Jovanović J; Schlueter M; Kritikou P; Wilson K; Myrén KJ
J Med Econ; 2018 Apr; 21(4):318-325. PubMed ID: 29139314
[TBL] [Abstract][Full Text] [Related]
13. Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A.
Sanabria M; Álvarez Román MT; Castaman G; Janbain M; Matsushita T; Meijer K; Oldenburg J; Friedl S; Reding MT
BMJ Open; 2021 Sep; 11(9):e044997. PubMed ID: 34475142
[TBL] [Abstract][Full Text] [Related]
14. Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect Comparison.
Hakimi Z; Santagostino E; Postma MJ; Nazir J
Adv Ther; 2021 Feb; 38(2):1263-1274. PubMed ID: 33377987
[TBL] [Abstract][Full Text] [Related]
15. Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe haemophilia A: final results of the PROTECT VIII extension study.
Reding MT; Pabinger I; Holme PA; Poulsen L; Negrier C; Chalasani P; Maas Enriquez M; Wang M; Meijer K; Mancuso ME; Lalezari S
Haemophilia; 2021 May; 27(3):e347-e356. PubMed ID: 33818853
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, prophylactic effects, and safety of a new recombinant FVIII formulated with sucrose (BAY 14-2222) in Japanese patients with hemophilia A.
Shirahata A; Fukutake K; Takamatsu J; Shima M; Yoshioka A
Int J Hematol; 2000 Jul; 72(1):101-7. PubMed ID: 10979218
[TBL] [Abstract][Full Text] [Related]
17. PROTECT VIII kids extension study: Long-term safety and efficacy of BAY 94-9027 (damoctocog alfa pegol) in children with severe haemophilia A.
Mancuso ME; Biss T; Fischer K; Maas Enriquez M; Steele M; Wang M; Tseneklidou-Stoeter D; Ahuja S; Kenet G
Haemophilia; 2021 May; 27(3):434-444. PubMed ID: 33724632
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations.
Bukkems LH; Preijers T; van Spengler MWF; Leebeek FWG; Cnossen MH; Mathôt RAA
Thromb Haemost; 2021 Jun; 121(6):731-740. PubMed ID: 33506481
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of simoctocog alfa versus extended half-life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching-adjusted indirect comparison method.
Kessler CM; Corrales-Medina FF; Mannucci PM; Jiménez-Yuste V; Tarantino MD
Eur J Haematol; 2023 Nov; 111(5):757-767. PubMed ID: 37587687
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
